

# Emerging Oncology Portfolio


Presentation at Barclays Global Healthcare Conference

March 11, 2025




moderna®

# Emerging oncology portfolio at Moderna uses mRNA technology to harness T-cells



## Cancer antigen therapies


Off-the-shelf therapies targeting shared antigens



## T-cell engagers

Multi-specific antibodies targeting different tumor antigens and T cells

*Includes programs partnered with Immatics*




## In vivo cell therapy

Tumor-targeting CAR-M to modulate tumor micro-environment

*Partnered with Carisma*

# Off-the-shelf cancer antigen therapies

**Cancer antigen therapies**  
Off-the-shelf therapies targeting shared antigens




## Therapies

### Immune-targeted antigen therapy

Targets immunosuppressive cells and mechanisms

## Development phase


Checkpoint Adaptive Immune Modulation Therapy (AIM-T) (mRNA-4359) in Phase 2



### Tumor-targeted antigen therapy

Targets tumor-specific and tumor-associated antigens shared across patients

IND open



### Cell therapy-enhancing antigen therapy

Encodes target of a cell therapy to enhance persistence and efficacy  
*Partnered with Immatics*

IND open

moderna

moderna®

The Moderna logo is centered on a solid red background. It features the word "moderna" in a white, lowercase, sans-serif font. A registered trademark symbol (®) is located at the top right of the letter "a". Directly beneath the text is a horizontal dashed line, composed of ten short white segments.